By Doug Macron

With an antisense-based drug already in a small phase I study, Bio-Path Holdings has begun eyeing the RNAi space with the hope that the ongoing clinical trial will confirm the efficacy of its proprietary delivery technology and help it secure capital to advance an siRNA therapeutic into the clinic.

Bio-Path was founded in 2007 to commercialize a drug-delivery approach developed at MD Anderson Cancer Center that involves the use of neutral lipids to carry oligonucleotide payloads.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.